Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CRVS 01.07.2025

SERA-AI Powered Highlights
Date of Upcoming Event:2025-01-15
Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference
Full Press ReleaseSEC FilingsOur CRVS Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
  • 01.07.2025 - Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1
  • 12.23.2024 - 4 Statement of changes in beneficial ownership of securities

BURLINGAME, Calif.,Jan. 07, 2025(GLOBE NEWSWIRE) --Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, will conduct one-on-one meetings with investors and present a corporate overview at the 43rdAnnualJ.P. Morgan Healthcare Conference, which is being held in San Francisco fromJanuary 13-16, 2025. The Company’s presentation will be on Wednesday, January 15 at 2:15 pm ET /11:15 am PT.

An audio webcast of the presentation will be available live and for 30 days following the event. The webcast may be accessed via theinvestor relationssection of the Corvus website.

About Corvus PharmaceuticalsCorvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visitwww.corvuspharma.com.

INVESTOR CONTACT:Leiv LeaChief Financial OfficerCorvus Pharmaceuticals, Inc.+1-650-900-4522llea@corvuspharma.com

MEDIA CONTACT:Sheryl SeapyReal Chemistry+1-949-903-4750sseapy@realchemistry.com

Primary Logo

Source: Corvus Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com